CompletedNCT07371325

Efficacy of Pediococcus Acidilactici as add-on to Antipsychotic Drugs on Metabolic Syndrome Disturbances in First-episode Psychosis and Schizophrenia Spectrum Disorders.

Medication studyAges 18–65Spain

The study in practice

Understand this study

Listed age limits: 18 years to 65 years.

Study clarity

Study start dateStarted: September 8, 2024

Recruitment status: Completed
Enrollment listed in the registry: 36
Sponsor: Manuel Jesús Cuesta Zurita
Sponsor type: Unknown or unclear
Study type: Drug
Intervention type: DIETARY_SUPPLEMENT, Medication / drug
Study phase: Not clearly listed
Locations: Spain
Age range: From 18 Years to 65 Years
Official registry ID: NCT07371325
Official title: Show the full official title
Efficacy of Pediococcus Acidilactici as add-on to Antipsychotic Drugs on Metabolic Syndrome Disturbances in First-episode Psychosis and Schizophrenia Spectrum Disorders. A Double-blind Placebo-controlled Trial.

Completed

Pamplona

FAQ

Who is behind this study?

The study sponsor is Manuel Jesús Cuesta Zurita.

Did this study involve medication?

Yes. The study involved medication, including Atypical antipsychotics (AAP).

Who was this study for?

Listed age limits: 18 years to 65 years.

Explore other studies

Answer a few simple questions to explore HopeStage studies by condition, country, and situation.